IPM Take
Huntington’s disease has had too many almost-moments.
Signals. Subgroups. Biological logic. Hope that briefly looked like direction, then ran into the hard wall of confirmatory evidence. PRECISE-HD matters because it is designed to ask the question again, more deliberately.
That is the right thing to do. But nobody should confuse trial initiation with progress for patients. Progress starts when a treatment can show that it changes the course of a disease families have watched move through generations.
Executive Summary
Ferrer and Prilenia announced initiation of PRECISE-HD, a confirmatory Phase III study of pridopidine in Huntington’s disease. Recruitment has begun in the United States, with additional countries expected to follow.
The study is planned to enrol approximately 400 participants with early to mid-stage Huntington’s disease across up to 75 sites globally, including the United States, the European Union, the United Kingdom and Canada. The trial is randomised, double-blind and placebo-controlled for 52 weeks, followed by a 104-week open-label extension that will compare long-term outcomes with matched external controls.
The study will assess disease progression, function, motor symptoms, cognition, speech and quality of life. PRECISE-HD is a trial launch, not an efficacy result. Pridopidine remains investigational.
Why it matters
- Patients / advocates: Huntington’s families need urgency, but they also need evidence that does not rest on fragile signals or retrospective hope.
- Clinicians: The trial may clarify whether pridopidine can affect function and progression in a defined early-to-mid disease population.
- Researchers / academia: The design shows how the field is trying to learn from earlier studies while still relying partly on external comparisons for longer-term follow-up.
- Regulators: Any future decision will depend on whether the blinded period produces clinically persuasive evidence, not simply whether longer-term modelling looks favourable.
Huntington’s disease is not only a diagnosis. It is a forecast.
Families know what may be coming. Movement changes. Thinking changes. Mood changes. Work, relationships and independence become harder to protect. The disease arrives with a biological explanation and still offers too little that can stop it.
That is why confirmatory trials carry emotional weight. They are not just research milestones. They are tests of whether a field is finally getting closer to something useful.
PRECISE-HD deserves attention because it is not pretending the old uncertainty is gone. It is enrolling a defined early-to-mid Huntington’s population and placing pridopidine against placebo in a 52-week controlled study. That is where the drug has to prove itself.
The open-label extension may add important long-term information, but external controls cannot do the same job as a concurrent placebo comparison. They can support interpretation. They cannot fully remove bias, population differences or the temptation to see a treatment effect where disease variability may still be speaking.
This is the evidence discipline Huntington’s needs.
Not cynicism. Not delay for the sake of delay. But a refusal to turn every new start into a breakthrough. Patients deserve trials that are ambitious enough to move quickly and rigorous enough to mean something when the results arrive.
PRECISE-HD has started. The field should watch closely, and patiently, because this is where promise either becomes evidence or joins the long list of Huntington’s almost-moments.
